Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study.

Ezat AA, Elfiky AA, Elshemey WM, Saleh NA.

Virusdisease. 2019 Jun;30(2):207-213. doi: 10.1007/s13337-019-00516-7. Epub 2019 Mar 21.

PMID:
31179358
2.

GRP78: A cell's response to stress.

Ibrahim IM, Abdelmalek DH, Elfiky AA.

Life Sci. 2019 Jun 1;226:156-163. doi: 10.1016/j.lfs.2019.04.022. Epub 2019 Apr 9. Review.

PMID:
30978349
3.

Applied Informatics Decision Support Tool for Mortality Predictions in Patients With Cancer.

Bertsimas D, Dunn J, Pawlowski C, Silberholz J, Weinstein A, Zhuo YD, Chen E, Elfiky AA.

JCO Clin Cancer Inform. 2018 Dec;2:1-11. doi: 10.1200/CCI.18.00003.

4.

Development and Application of a Machine Learning Approach to Assess Short-term Mortality Risk Among Patients With Cancer Starting Chemotherapy.

Elfiky AA, Pany MJ, Parikh RB, Obermeyer Z.

JAMA Netw Open. 2018 Jul 6;1(3):e180926. doi: 10.1001/jamanetworkopen.2018.0926.

5.

Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study.

Elfiky AA.

Med Chem. 2019;15(2):130-137. doi: 10.2174/1573406414666181015152511.

PMID:
30324891
6.

Accreditation Standard Guideline Initiative for Tai Chi and Qigong Instructors and Training Institutions.

Oh B, Yeung A, Klein P, Larkey L, Ee C, Zaslawski C, Knobf T, Payne P, Stener-Victorin E, Lee R, Choi W, Chun M, Bonucci M, Lang HD, Pavlakis N, Boyle F, Clarke S, Back M, Yang P, Wei Y, Guo X, Weng CD, Irwin MR, Elfiky AA, Rosenthal D.

Medicines (Basel). 2018 Jun 8;5(2). pii: E51. doi: 10.3390/medicines5020051.

7.

In silico estrogen-like activity and in vivo osteoclastogenesis inhibitory effect of Cicer arietinum extract.

Sayed AA, Elfiky AA.

Cell Mol Biol (Noisy-le-grand). 2018 Apr 30;64(5):29-39.

PMID:
29729691
8.

Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures.

Elfiky AA, Ismail AM.

SAR QSAR Environ Res. 2018 May;29(5):409-418. doi: 10.1080/1062936X.2018.1454981.

PMID:
29652194
9.

Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds.

Elfiky AA, Elshemey WM.

J Med Virol. 2018 Jan;90(1):13-18. doi: 10.1002/jmv.24934. Epub 2017 Sep 18.

PMID:
28922464
10.

Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses.

Elfiky AA, Mahdy SM, Elshemey WM.

J Med Virol. 2017 Jun;89(6):1040-1047. doi: 10.1002/jmv.24736. Epub 2017 Feb 16.

PMID:
27864902
11.

Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials.

Elfiky AA.

J Med Virol. 2016 Dec;88(12):2044-2051. doi: 10.1002/jmv.24678. Epub 2016 Sep 20.

PMID:
27604059
12.

Assessment and management of advanced adrenocortical carcinoma using a precision oncology care model.

Elfiky AA, Krishnan Nair HK.

Discov Med. 2016 Jan;21(113):49-56. Review.

13.

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL.

Clin Genitourin Cancer. 2016 Aug;14(4):e299-305. doi: 10.1016/j.clgc.2015.12.008. Epub 2015 Dec 17.

PMID:
26778006
14.

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME.

Clin Genitourin Cancer. 2015 Apr;13(2):113-23. doi: 10.1016/j.clgc.2014.08.007. Epub 2014 Oct 22.

15.

Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer.

Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL.

J Geriatr Oncol. 2014 Oct 1;5(4):352-8. doi: 10.1016/j.jgo.2014.05.001. Epub 2014 May 23.

PMID:
24862107
16.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE.

Cancer Discov. 2014 May;4(5):546-53. doi: 10.1158/2159-8290.CD-13-0353. Epub 2014 Mar 13.

17.

A novel community-based delivery model to combat cancer disparities.

Waldman LT, Svoboda L, Young BF, Abel GA, Berlin S, Elfiky AA, Freedman RA, Drews M, Holland L, Lathan CS.

Healthc (Amst). 2013 Dec;1(3-4):123-9. doi: 10.1016/j.hjdsi.2013.09.004. Epub 2013 Dec 10. No abstract available.

PMID:
26249781
18.

Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes.

Elfiky AA, Elshemey WM, Gawad WA, Desoky OS.

Protein J. 2013 Jan;32(1):75-80. doi: 10.1007/s10930-013-9462-9.

PMID:
23322006
19.

The PI3 kinase signaling pathway in prostate cancer.

Elfiky AA, Jiang Z.

Curr Cancer Drug Targets. 2013 Feb;13(2):157-64. Review.

PMID:
23215719
20.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M.

J Clin Oncol. 2013 Feb 1;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.

21.

Novel molecular targets for the therapy of renal cell carcinoma.

Elfiky AA, Sonpavde G.

Discov Med. 2012 Jun;13(73):461-71.

22.

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.

Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, Robert CL, Kluger HM.

J Transl Med. 2011 Aug 11;9:133. doi: 10.1186/1479-5876-9-133.

23.

Correlation to protein conformation of Wide-angle X-ray Scatter parameters.

Elshemey WM, Elfiky AA, Gawad WA.

Protein J. 2010 Nov;29(8):545-50. doi: 10.1007/s10930-010-9291-z.

PMID:
21046443
24.

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.

Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.

Urol Oncol. 2011 Nov-Dec;29(6):756-63. doi: 10.1016/j.urolonc.2010.01.008. Epub 2010 May 6.

PMID:
20451414
25.

Novel agents for advanced bladder cancer.

Sonpavde G, Elfiky AA, Rosenberg JE.

Ther Adv Med Oncol. 2009 Jul;1(1):37-50. doi: 10.1177/1758834009337776.

26.

Targeting angiogenesis in bladder cancer.

Elfiky AA, Rosenberg JE.

Curr Oncol Rep. 2009 May;11(3):244-9. Review.

PMID:
19336017
27.

Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients.

Saif MW, Elfiky AA.

J Support Oncol. 2007 Jul-Aug;5(7):337-43. No abstract available.

PMID:
17708124
28.

The developing trend of monoclonal antibodies in the treatment of colorectal cancer.

Elfiky AA, Saif MW.

Expert Opin Biol Ther. 2007 Jun;7(6):871-83. Review.

PMID:
17555372

Supplemental Content

Loading ...
Support Center